Precipio Launches Covid-19 Antibody Test in its CLIA laboratory
Completed the internal validation of the FDA-approved COVID-19 serology antibody test in its CLIA laboratory.
Launched the test commercially to its pathology customer base (phase 1)
Upon obtaining further approval for expanded use by FDA, phase 2 will broaden our distribution to POC (point-of-care) healthcare facilities including hospitals, medical centers, urgent care facilities and physician practices.
Precipio is currently able to process 1,000 tests per day, increasing testing capacity to 10,000 tests per day by the end of Q3-20 as demand grows.
Reimbursement is approximately $45 per test.
finance.yahoo.com/news/precipio-launches-covid-19-antibody-144500207.html?guce_referrer=aHR0cHM6Ly9maW52aXouY29tL3F1b3RlLmFzaHg_dD1QUlBPJnR5PWMmcD1kJmI9MQ&guce_referrer_sig=AQAAAIl9m1hj4H-3MsZAxiayo-NQnjvo2rEKFOAnX2CULHu3EfxrOtBdzBHS5JxwiUddryO30q2xw05w2HsXBFCkmVwHVxwCXoDIlLnCtb2-bIIwtbBYeD3LDZ5CaBtOpVF4PMq-IkJL49uUgLvhPfO_YGNI67xoFUUV9HgoBuc0VWBp&_guc_consent_skip=1596613149
Completed the internal validation of the FDA-approved COVID-19 serology antibody test in its CLIA laboratory.
Launched the test commercially to its pathology customer base (phase 1)
Upon obtaining further approval for expanded use by FDA, phase 2 will broaden our distribution to POC (point-of-care) healthcare facilities including hospitals, medical centers, urgent care facilities and physician practices.
Precipio is currently able to process 1,000 tests per day, increasing testing capacity to 10,000 tests per day by the end of Q3-20 as demand grows.
Reimbursement is approximately $45 per test.
finance.yahoo.com/news/precipio-launches-covid-19-antibody-144500207.html?guce_referrer=aHR0cHM6Ly9maW52aXouY29tL3F1b3RlLmFzaHg_dD1QUlBPJnR5PWMmcD1kJmI9MQ&guce_referrer_sig=AQAAAIl9m1hj4H-3MsZAxiayo-NQnjvo2rEKFOAnX2CULHu3EfxrOtBdzBHS5JxwiUddryO30q2xw05w2HsXBFCkmVwHVxwCXoDIlLnCtb2-bIIwtbBYeD3LDZ5CaBtOpVF4PMq-IkJL49uUgLvhPfO_YGNI67xoFUUV9HgoBuc0VWBp&_guc_consent_skip=1596613149
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.